Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-24-019383
Filing Date
2024-02-23
Accepted
2024-02-23 16:18:59
Documents
7
Effectiveness Date
2024-02-23

Document Format Files

Seq Description Document Type Size
1 S-8 sabs_s-8_20240221_2024ev.htm S-8 130178
2 EX-5.1 sabs-ex5_1.htm EX-5.1 27720
3 EX-23.1 sabs-ex23_1.htm EX-23.1 3858
4 EX-99.2 sabs-ex99_2.htm EX-99.2 241860
5 EX-FILING FEES sabs-exfiling_fees.htm EX-FILING FEES 35843
6 GRAPHIC img84541401_0.jpg GRAPHIC 18837
7 GRAPHIC img84541401_1.jpg GRAPHIC 18837
  Complete submission text file 0000950170-24-019383.txt   492773
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-277314 | Film No.: 24671485
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)